SCHEDULE 13G/A: Cormorant Asset Management Amends VYNE Therapeutics Stake, Correcting Beneficial Ownership to 9.99%

Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, correcting their beneficial ownership in VYNE Therapeutics Inc. to 1,849,590 shares, representing 9.99% of the common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen reported beneficial ownership of 1,849,590 shares of VYNE Therapeutics Inc. Common Stock.
• This represents 9.99% of the outstanding Common Stock.
• The filing is an Amendment No. 2 to correct an inadvertent error in a previous Schedule 13G filed on May 15, 2025.
• The reported shares include those issuable upon the exercise of pre-funded warrants.
• Exercise of these warrants is subject to a limitation preventing beneficial ownership from exceeding 9.99%.
• Without this limitation, the warrants would be exercisable for up to 3,060,143 shares.
• The percentage is calculated based on 16,664,892 shares of Common Stock outstanding as of May 1, 2025, as reported by VYNE Therapeutics Inc. in its Form 10-Q.
• Cormorant Global Healthcare Master Fund, LP also has the right to receive dividends or proceeds from the sale of more than 5% of the Common Stock upon warrant exercise.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine regulatory update correcting a previous error, which is a positive for compliance. The continued significant stake by a major investor is also a positive signal, though the 9.99% cap on warrant exercise is a minor limiting factor.

Positives

• A significant institutional investor (Cormorant Asset Management) maintains a substantial stake, indicating continued interest in VYNE Therapeutics.
• The correction of the filing demonstrates transparency and adherence to regulatory requirements.

Negatives

• The filing itself is a correction of a previous error, which, while stated as inadvertent, implies a minor administrative oversight.
• The 9.99% beneficial ownership cap on warrant exercise limits the immediate potential for the reporting persons to increase their stake beyond this threshold.

Risks

• The beneficial ownership is capped at 9.99% due to a limitation on warrant exercise, which could restrict the investor's ability to increase their stake beyond this threshold without further disclosures or actions.
• The value of the pre-funded warrants is tied to the performance of VYNE Therapeutics' common stock.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's operations or financial performance, focusing solely on beneficial ownership reporting.

Management Comments

• The filing includes a certification from Bihua Chen, Managing Member of Cormorant Asset Management, LP, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing is a standard regulatory disclosure for significant beneficial ownership. It indicates continued institutional interest in VYNE Therapeutics Inc. within the broader market, but does not provide specific industry-wide trends or competitive analysis.

Comparison to Industry Standards

• This document is a beneficial ownership filing (Schedule 13G) and does not contain financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects. It solely reports a passive investment stake.

Related Party Transactions

• Cormorant Global Healthcare Master Fund, LP, a private investment vehicle for which Cormorant Asset Management, LP serves as investment adviser, would have the right to receive dividends or proceeds from the sale of more than five percent of the Common Stock upon the exercise of the described Warrants.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and its passive nature. The correction ensures accurate public record of ownership.
• Regulatory Authorities: Demonstrates compliance with SEC reporting requirements by correcting a previous error.

Next Steps

• The document does not specify future actions or milestones for the issuer or the reporting persons beyond the regulatory filing itself.

Key Dates

Keywords

VYNE Therapeutics, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, SEC Filing, Institutional Investor, Investment Adviser